Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested
Psoriasis Clinical Trials
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested
Dermatology Clinical Trials
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested
Pediatric Dermatology Clinical Trials
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested
Mirena Extension Trial
The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Eligibility
Inclusion Criteria:
- Signed and dated informed consent
- Women, 18 to 35 years of age at the time of screening (visit 1) who are currently
using Mirena for contraception or for contraception and heavy menstrual bleeding. The
duration of use of the current Mirena has to be at least 4 years 6 months at the start
of screening phase but not more than 5 years at visit 2 and the woman is willing to
continue with its use and has a continuing need for contraception.
- Normal or clinically insignificant cervical smear not requiring further follow up
Exclusion Criteria:
- Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
- Pregnancy or suspicion of pregnancy
- Uterine bleeding of unknown etiology
- Untreated acute cervicitis or vaginitis or other lower genital tract infections
- Increased susceptibility to pelvic infection
- Acute pelvic inflammatory disease (PID) or a history of PID unless successfully
treated and which, in the investigator's opinion, has not negatively affected
subject's fertility
- Congenital or acquired uterine anomaly if it distorts the uterine cavity
- History of, diagnosed or suspected genital or other malignancy and untreated cervical
dysplasia
- Any active acute liver disease or liver tumor (benign or malignant)
- Clinically significant endometrial polyp(s)
Ages Eligible for Study
18 Years - 35 Years
Genders Eligible for Study
Female
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kathryn Batham
650-724-7826
I'm interested